CN1649577A - 预防和/或治疗心血管疾病和/或相关的心衰 - Google Patents

预防和/或治疗心血管疾病和/或相关的心衰 Download PDF

Info

Publication number
CN1649577A
CN1649577A CNA038101513A CN03810151A CN1649577A CN 1649577 A CN1649577 A CN 1649577A CN A038101513 A CNA038101513 A CN A038101513A CN 03810151 A CN03810151 A CN 03810151A CN 1649577 A CN1649577 A CN 1649577A
Authority
CN
China
Prior art keywords
patient
copper
diabetes
cardiomyopathy
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038101513A
Other languages
English (en)
Chinese (zh)
Inventor
G·J·S·库珀
J·R·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Publication of CN1649577A publication Critical patent/CN1649577A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CNA038101513A 2002-03-08 2003-03-10 预防和/或治疗心血管疾病和/或相关的心衰 Pending CN1649577A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NZ517721 2002-03-08
NZ51772102 2002-03-08
NZ51772502 2002-03-11
NZ517725 2002-03-11
US36438202P 2002-03-12 2002-03-12
US60/364,382 2002-03-12

Publications (1)

Publication Number Publication Date
CN1649577A true CN1649577A (zh) 2005-08-03

Family

ID=28046135

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038101513A Pending CN1649577A (zh) 2002-03-08 2003-03-10 预防和/或治疗心血管疾病和/或相关的心衰

Country Status (10)

Country Link
US (4) US6951890B2 (cg-RX-API-DMAC10.html)
EP (2) EP2500018B1 (cg-RX-API-DMAC10.html)
JP (1) JP4860906B2 (cg-RX-API-DMAC10.html)
CN (1) CN1649577A (cg-RX-API-DMAC10.html)
AT (1) ATE555782T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003225442B2 (cg-RX-API-DMAC10.html)
CA (1) CA2478997C (cg-RX-API-DMAC10.html)
DK (2) DK1487431T3 (cg-RX-API-DMAC10.html)
ES (1) ES2386782T3 (cg-RX-API-DMAC10.html)
WO (1) WO2003077901A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
WO2021057680A1 (zh) * 2019-09-23 2021-04-01 张建国 2,4-二羟基苯甲酸或其同分异构体在铁过载引发相关疾病或状况中的应用
CN114867474A (zh) * 2019-06-17 2022-08-05 菲勒拉新西兰有限责任公司 中枢神经系统病症的联合治疗

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
EP2500018B1 (en) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure
US6855340B2 (en) * 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060100278A1 (en) * 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
US20050096256A1 (en) 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
CA2550505A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US7563460B2 (en) * 2004-02-26 2009-07-21 Med Five, Inc. Enteric coated oral pharmaceutical to erode kidney stones
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1778618B1 (en) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthesis of triethylenetetramines
HU227588B1 (hu) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
WO2006104402A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
WO2006104398A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
EP1874285B1 (en) * 2005-04-07 2009-10-07 Astrum Therapeutics Pty, Ltd. Complementary compositions to reduce blood glucose levels and treat diabetes
AU2006240568A1 (en) * 2005-04-25 2006-11-02 Philera New Zealand Limited Copper regulation evaluation and therapy
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1948160A4 (en) * 2005-11-09 2013-07-10 Protemix Corp Ltd TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS
JP2009523175A (ja) * 2006-01-10 2009-06-18 パイペックス，インコーポレイテッド 目標とされる安定な銅状態を達成及び維持して銅関連中枢神経系疾患を予防及び治療するための医薬組成物及び方法
KR100821649B1 (ko) 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
CN101437503A (zh) * 2006-02-21 2009-05-20 阿斯特鲁姆医疗有限公司 用于降低血糖水平和治疗糖尿病的组合物
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
US20090270420A1 (en) * 2006-06-01 2009-10-29 Sobel Burton E Methods for inhibiting cardiac pai-1
KR100816798B1 (ko) * 2006-09-08 2008-03-25 (주)팜스웰 의약용 트리에틸렌테트라민 이염산염의 제조방법
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
US20100311092A1 (en) * 2007-11-30 2010-12-09 Kurland Irwin J Metabolic fuel switching biomarker
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
US20100234906A1 (en) * 2009-03-16 2010-09-16 Pacesetter, Inc. System and method for controlling rate-adaptive pacing based on a cardiac force-frequency relation detected by an implantable medical device
JP5896375B2 (ja) 2011-09-09 2016-03-30 池田食研株式会社 改変型グルコース脱水素酵素遺伝子
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CZ307108B6 (cs) * 2013-09-06 2018-01-17 Vysoké Učení Technické V Brně Multifunkční poloprovozní jednotka pro snižování polutantů z odpadního plynu
EP2845640B1 (en) 2013-09-06 2018-10-24 Vysoké Ucení Technické V Brne Multifunction operation unit for reducing pollutant concentration in a waste gas
JP2018505407A (ja) 2015-01-07 2018-02-22 ノッティンガム ユニバーシティ ホスピタルズ エヌエイチエス トラストＮｏｔｔｉｎｇｈａｍ Ｕｎｉｖｅｒｓｉｔｙ Ｈｏｓｐｉｔａｌｓ Ｎｈｓ Ｔｒｕｓｔ 検査方法、原子種の使用方法、検査装置、及び、テストキット
WO2017049529A1 (en) * 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
WO2018005990A2 (en) * 2016-07-01 2018-01-04 Marshall University Research Corporation Compositions and methods for treating uremic cardiomyopathy
TWI902661B (zh) 2018-05-04 2025-11-01 法商奧法蘭股份公司 三伸乙基四胺四鹽酸鹽之結晶型及其醫藥用途
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP3947433A4 (en) * 2019-04-02 2022-11-23 The Regents of The University of Michigan USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASES
CN112138024A (zh) 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
GB2612210B (en) * 2020-06-24 2025-08-27 Reverspah Llc Pharmaceutical composition comprising a tetrathiomolybdate salt and a diethylcarbamazine
CN115998955B (zh) * 2022-12-09 2024-12-20 首都医科大学附属北京安贞医院 一种静脉桥的醛铬复合交联方法
KR102878403B1 (ko) * 2023-01-25 2025-10-28 김성국 동맥경화 치료용 킬레이션 약학 조성물 및 체외 역박동기를 이용한 동맥경화 치료용 킬레이션 약학 조성물의 투여방법

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791988A (en) 1972-03-23 1974-02-12 Hoffmann La Roche Diagnostic test for glucose
PL105793B1 (pl) 1977-11-24 1979-10-31 Sposob otrzymywania soli kwasow dwukarboksylowych i poliamin
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4323558A (en) 1979-09-10 1982-04-06 Nelson Research & Development Co. Topical trien containing pharmaceutical compositions and methods of use
US4371374A (en) 1980-11-17 1983-02-01 The Rockefeller University Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine
JPS57144215A (en) 1981-03-02 1982-09-06 Nippon Nousan Kogyo Kk Composition for improving lipometabolism
DE3217071A1 (de) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5852009A (en) 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
EP0302065B1 (en) 1986-03-21 1994-08-10 Eurasiam Laboratories, Inc. Pharmaceutical compositions
CH666814A5 (it) 1986-07-24 1988-08-31 Inpharzam Int Sa Composizione farmaceutica idrosolubile contenente n-acetil-cisteina.
CH667590A5 (it) 1986-07-24 1988-10-31 Inpharzam Int Sa Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. .
US4866090A (en) 1988-01-07 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
EP0331014A3 (de) 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
JPH01294631A (ja) 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd 糖尿性疾患治療予防剤及び飲食、し好物
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
AU667069B2 (en) 1991-12-06 1996-03-07 North Shore University Hospital Research Corporation Method of reducing medical device related infections
US5246970A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
JP3157622B2 (ja) 1992-06-05 2001-04-16 株式会社ミツカングループ本社 フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法
JPH06298738A (ja) * 1993-04-15 1994-10-25 Yamanouchi Pharmaceut Co Ltd ５−アミノピラゾール誘導体
JPH07118148A (ja) 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
AU1447095A (en) 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US5854271A (en) 1994-05-02 1998-12-29 Cytos Pharmaceuticals, L.L.C. Effective method for the amelioration and prevention of tissue and cellular damage
AU4134996A (en) 1994-10-25 1996-05-15 Washington University Method of inhibiting nitric oxide formation
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
JP3988838B2 (ja) * 1996-05-29 2007-10-10 日本製粉株式会社 化粧料
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
EP1007048A4 (en) 1997-03-11 2004-09-22 Gen Hospital Corp IDENTIFICATION OF MEANS FOR TREATING ALZHEIMERISCHEN DISEASE
JPH10324629A (ja) * 1997-03-28 1998-12-08 Otsuka Pharmaceut Co Ltd Ａｇｅ生成阻害組成物
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6576672B1 (en) 1998-08-21 2003-06-10 Michael A. Murphy Polyamine treatment of neurological disorders
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US5972985A (en) 1997-11-03 1999-10-26 Cytos Pharmaceuticals, Llc Histidine containing nutriceutical compositions
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states
EP1234585A3 (en) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
CN1320160A (zh) 1998-09-25 2001-10-31 格利科克斯有限公司 果糖胺氧化酶测定的方法和材料
JP2000204037A (ja) 1999-01-12 2000-07-25 Tsumura & Co 筋萎縮性側索硬化症治療薬
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
EP1185558A4 (en) 1999-06-18 2006-02-15 Protemix Discovery Ltd PEPTIDES WITH PREPTID FUNCTIONALITY
US20030050434A1 (en) 1999-06-18 2003-03-13 Cooper Garth J.S. Peptide
US20030166561A1 (en) 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
DE60129427T3 (de) 2000-05-11 2014-07-24 The Procter & Gamble Company Hochkonzentrierte wäscheweichspülerzusammensetzungen und diese enthaltende mittel
EP1370254B1 (en) 2000-12-01 2008-01-16 Radical Vision Therapeutics Inc. Copper chelators for treating ocular inflammation
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
EP1373893A2 (en) 2001-03-30 2004-01-02 Protemix Corporation Limited Phosphoprotein target for insulin and its antagonists
WO2003002732A1 (en) 2001-06-27 2003-01-09 Biovitrum Ab Citrate lyase poly peptides
EP1417055A4 (en) 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
EP1461068A4 (en) 2001-11-26 2006-03-29 Protemix Corp Ltd METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
US20040038861A1 (en) 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US7144706B2 (en) 2002-01-03 2006-12-05 Duke University Methods of modulating localization and physiological function of IP3 receptors
JP2005535561A (ja) 2002-01-18 2005-11-24 プロテミックス コーポレイション リミティド アディポネクチンのグリコアイソフォームとその使用
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
CN1688299A (zh) 2002-01-29 2005-10-26 普罗特米克斯公司 抑制细胞毒性蛋白构象异构体
AU2003225440A1 (en) 2002-03-01 2003-09-16 Protemix Discovery Limited Falp proteins
EP2500018B1 (en) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure
AU2003222513A1 (en) * 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
EP1494658B1 (en) 2002-04-03 2006-01-04 Puleva Biotech, S.A. Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
WO2003093311A1 (en) 2002-04-29 2003-11-13 Protemix Corporation Limited Proteins with deglycating activities and methods of using same
US6855340B2 (en) 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
JP2003343552A (ja) * 2002-05-27 2003-12-03 Koyo Seiko Co Ltd 円錐ころ軸受
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
WO2004012760A1 (en) 2002-08-01 2004-02-12 Auckland Uniservices Limited Preptin methods of use
EP1534321A1 (en) 2002-08-01 2005-06-01 Protemix Corporation Limited Methods of use of compounds with preptin function
US20040142393A1 (en) 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
AU2003214725A1 (en) 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
AU2003285686A1 (en) 2002-12-23 2004-07-14 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1606292A2 (en) 2003-03-21 2005-12-21 Palumed SA Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
AU2004238285A1 (en) 2003-05-07 2004-11-25 Dmi Biosciences, Inc Oral care methods and products
US7176239B2 (en) 2003-07-11 2007-02-13 Suming Wang Methods and compositions for treatment of Ataxia-telangeictasia
WO2005040205A1 (en) 2003-10-28 2005-05-06 Protemix Discovery Limited Peptides with anti-obesity activity and other related uses
CA2550505A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
EP1778618B1 (en) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthesis of triethylenetetramines
WO2006068516A1 (en) 2004-12-20 2006-06-29 Protemix Corporation Limited Implantable medical devices coated with or containing copper chelating compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
CN114867474A (zh) * 2019-06-17 2022-08-05 菲勒拉新西兰有限责任公司 中枢神经系统病症的联合治疗
WO2021057680A1 (zh) * 2019-09-23 2021-04-01 张建国 2,4-二羟基苯甲酸或其同分异构体在铁过载引发相关疾病或状况中的应用

Also Published As

Publication number Publication date
AU2003225442A1 (en) 2003-09-29
US20110212188A1 (en) 2011-09-01
US8563538B2 (en) 2013-10-22
JP2005533003A (ja) 2005-11-04
CA2478997C (en) 2013-12-17
CA2478997A1 (en) 2003-09-25
EP2500018A1 (en) 2012-09-19
US20060009534A1 (en) 2006-01-12
US20140113969A1 (en) 2014-04-24
AU2003225442B2 (en) 2010-02-04
US8987244B2 (en) 2015-03-24
WO2003077901A1 (en) 2003-09-25
US6951890B2 (en) 2005-10-04
US20030203973A1 (en) 2003-10-30
EP2500018B1 (en) 2017-07-19
DK2500018T3 (en) 2017-10-02
JP4860906B2 (ja) 2012-01-25
EP1487431A4 (en) 2006-10-25
HK1071313A1 (en) 2005-07-15
EP1487431B1 (en) 2012-05-02
DK1487431T3 (da) 2012-08-20
US8034799B2 (en) 2011-10-11
ES2386782T3 (es) 2012-08-30
EP1487431A1 (en) 2004-12-22
ATE555782T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
US6951890B2 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
Wang et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system
CN1244801A (zh) 用于糖尿病的磺酰脲类－格列酮类协同联合给药
CN1165310C (zh) 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物)
CN1253150C (zh) 单独的或与抗血小板聚集药物联合的Xa因子抑制剂
CN1471393A (zh) 神经性和神经心理性疾病的治疗方法
JP2005533003A5 (cg-RX-API-DMAC10.html)
CN1384755A (zh) 新型exendin激动剂制剂及其给药方法
CN1622941A (zh) 基于谷氨酰胺酰基的dpiv抑制剂
CN1816524A (zh) 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
Dhanesha et al. Exendin‐4 ameliorates diabetic symptoms through activation of glucokinase
CN1209066A (zh) 用于抑制疼痛、炎症、痉挛和再狭窄的供血管内应用的冲洗液和方法
CN1642904A (zh) 那格列奈的盐
WO2005123132A2 (en) Use of liver-selective glucokinase activators
HK1043316A1 (zh) 去鐵酮的新用途
Ang et al. The impact of a single dose of whey protein on glucose flux and metabolite profiles in normoglycemic males: insights into glucagon and insulin biology
Liu et al. CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients
CN1208066C (zh) 应用环醚制备影响葡萄糖耐量的药物
CN1822827A (zh) α－酮戊二酸用于治疗营养不良或高血浆葡萄糖症状的用途
Simonsen et al. Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto–Kakizaki rats
HK1039904A1 (zh) 评估糖尿病患者发生糖尿病相关病理情况的危险度的方法
CN1646167A (zh) 代谢综合症的治疗
CA2828595C (en) Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
van der Zwan et al. Homoarginine and arginine are antagonistically related to blood pressure
Said Journal of Diabetes and Metabolism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication